Evidence Hub

Pharmacokinetics and bioequivalence of dexlansoprazole delayed release capsules in Beagle dogs

Qing Meng

Shenyang Yaoke Daxue xuebao, 2015

Abstract

Objective To study the pharmacokinetics profile of dexlansoprazole delayed release capsules in beagle dogs.Methods Ten Beagle dogs were administered with an oral single and multiple doses of test and reference capsules of dexlansoprazole in a randomized two-way cross-over test and the plasma concentrations of dexlansoprazole were determined by LC-MS/MS method.The pharmacokinetic parameters were calculated by Win Nolin 6.1 software.Results The main pharmacokinetic parameters of dexlansoprazole test and reference capsules after a single dose were as follows: t1 /2=(1.2 ± 1.0) and(1.0 ± 0.7) h; tmax=(2.3 ± 1.0)and(2.6 ± 1.1) h; ρmax=(2.388 6 ± 0.639 1) and(2.348 5 ± 0.728 6)mg·L-1; AUC0-t=(5.601 4 ±1.627 4) and(5.602 3 ± 1.865 7)mg·h·L-1; AUC0-∞=(5.653 6 ± 1.630 9) and(5.657 5 ± 1.878 6)mg·h·L-1,respectively.The relative bioavailability was(101.6 ± 8.9) %.The main pharmacokinetic parameters after multiple doses were similar to those after a single dose.Conclusions There is a significant individual difference on dexlansoprazole in Beagle dogs.The two kinds of dexlansoprazole delayed release capsules are bioequivalent in Beagle dogs.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free